Novartis (NOV +0.8%) will take a $590M charge in Q3 linked to the discontinuation of the...

|By:, SA News Editor

Novartis (NOV +0.8%) will take a $590M charge in Q3 linked to the discontinuation of the development of two experimental drugs. The news is actually being viewed as a positive, as analysts say it "[gives] the market clarity over the company's pipeline" and reflects Novartis' efforts to restructure.